CLARITAS PHARMACEUTICALS INC.
OOTC:CLAZF0.00
USD
0.00
(0.00%)
ISIN
CA1806342061
CUSIP
180634206
Return %
Stock
S&P 500
1Y
0.00
13.14
3Y
-90.00
80.78
5Y
-100.00
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Robert Edward Farrell
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 4040 Civic Center Drive San Rafael CA United States 94903
- IPO Date
- May 19, 2005
- Website
- claritaspharma.com
- Similar Companies
- Business
- Claritas Pharmaceuticals, Inc. (CLAZF) is a clinical-stage specialty pharmaceutical company that develops and commercializes therapies addressing unmet medical needs in areas including pulmonary arterial hypertension and pain management; its lead product candidate, R-107, is a small-molecule therapeutic in Phase 1 clinical trials targeting pulmonary arterial hypertension with plans for a subsequent Phase 2a study, while CLA-1816 advances in preclinical development as an alpha3 glycine receptor agonist for pain relief. Founded in 2014 and headquartered at 4040 Civic Center Drive, Suite 200, San Rafael, California, the company, formerly known as Kalytera Therapeutics, Inc., rebranded to Claritas Pharmaceuticals, Inc. in April 2021 and primarily operates in North America with clinical activities extending to Australia. Recent developments include approval from OTC Markets to uplist its common shares to the OTCQB Venture Market for enhanced trading visibility and a $5 million equity financing facility secured with Alumina Partners (Ontario) Ltd. to support ongoing operations and pipeline advancement.